CZ295194B6 - Orální prostředky s řízeným uvolňováním obsahující levosimendan - Google Patents

Orální prostředky s řízeným uvolňováním obsahující levosimendan Download PDF

Info

Publication number
CZ295194B6
CZ295194B6 CZ20003780A CZ20003780A CZ295194B6 CZ 295194 B6 CZ295194 B6 CZ 295194B6 CZ 20003780 A CZ20003780 A CZ 20003780A CZ 20003780 A CZ20003780 A CZ 20003780A CZ 295194 B6 CZ295194 B6 CZ 295194B6
Authority
CZ
Czechia
Prior art keywords
levosimendan
composition
release
controlled release
drug
Prior art date
Application number
CZ20003780A
Other languages
Czech (cs)
English (en)
Other versions
CZ20003780A3 (en
Inventor
Ilkka Larma
Maarit BÄCKMAN
Saila Antila
Lasse Lehtonen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ295194(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of CZ20003780A3 publication Critical patent/CZ20003780A3/cs
Publication of CZ295194B6 publication Critical patent/CZ295194B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
CZ20003780A 1998-04-23 1999-04-23 Orální prostředky s řízeným uvolňováním obsahující levosimendan CZ295194B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia

Publications (2)

Publication Number Publication Date
CZ20003780A3 CZ20003780A3 (en) 2001-05-16
CZ295194B6 true CZ295194B6 (cs) 2005-06-15

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20003780A CZ295194B6 (cs) 1998-04-23 1999-04-23 Orální prostředky s řízeným uvolňováním obsahující levosimendan

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
SK15542000A3 (sk) 2001-08-06
WO1999055305A2 (en) 1999-11-04
ATE258425T1 (de) 2004-02-15
GEP20032906B (en) 2003-02-25
CZ20003780A3 (en) 2001-05-16
UA68376C2 (en) 2004-08-16
TWI224507B (en) 2004-12-01
ES2215379T3 (es) 2004-10-01
HRP20000704B1 (hr) 2009-11-30
YU63900A (sh) 2003-07-07
MXPA00010367A (es) 2002-06-04
RS49962B (sr) 2008-09-29
AU3524699A (en) 1999-11-16
SI1071397T1 (en) 2004-06-30
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
US7045147B1 (en) 2006-05-16
SK285427B6 (sk) 2007-01-04
HUP0101458A2 (hu) 2002-03-28
EP1071397B1 (en) 2004-01-28
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
AU756641B2 (en) 2003-01-16
PL197447B1 (pl) 2008-03-31
CN1301163A (zh) 2001-06-27
NO329809B1 (no) 2010-12-20
PT1071397E (pt) 2004-06-30
JP4566402B2 (ja) 2010-10-20
ID27987A (id) 2001-05-03
CA2329234C (en) 2008-06-10
PL344078A1 (en) 2001-09-24
EE04220B1 (et) 2004-02-16
EA002829B1 (ru) 2002-10-31
FI980901A7 (fi) 1999-10-24
IL138951A (en) 2006-10-31
KR20010071172A (ko) 2001-07-28
JP2002512946A (ja) 2002-05-08
DE69914472T2 (de) 2004-11-11
BG64839B1 (bg) 2006-06-30
WO1999055305A3 (en) 1999-12-29
JP2010083900A (ja) 2010-04-15
EA200001098A1 (ru) 2001-04-23
NO20005313D0 (no) 2000-10-20
IL138951A0 (en) 2001-11-25
EE200000617A (et) 2002-06-17
BR9909869A (pt) 2000-12-19
KR100960597B1 (ko) 2010-06-07
TR200003102T2 (tr) 2001-02-21
FI980901A0 (fi) 1998-04-23
EP1071397A2 (en) 2001-01-31
HK1034032A1 (en) 2001-10-12
NZ507453A (en) 2003-02-28
NO20005313L (no) 2000-11-21
ZA200005632B (en) 2002-01-14
CO5070607A1 (es) 2001-08-28
DK1071397T3 (da) 2004-04-05
DE69914472D1 (de) 2004-03-04
CN1248691C (zh) 2006-04-05
AR019096A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
RU2311903C2 (ru) Таблетки тамзулосина
CN100402021C (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
US6531151B1 (en) Composition containing hydroxypropylmethylcellulose and/or ethylcellulose as disintegrants and process for producing it
JP2010083900A (ja) レボシメンダンの制御放出経口用組成物
CN116159033B (zh) 一种氨氯地平贝那普利固体制剂及其制备工艺
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
WO1998005306A1 (en) Controlled release tablet formulation of isosorbide-5-mononitrate
US20040197404A1 (en) Extended release oral dosage form
SK287298B6 (sk) Tuhý perorálny farmaceutický prostriedok vo forme tabliet s obsahom derivátu kyseliny bifosfónovej substituovaného aminoskupinami a spôsob jeho výroby
CN114588124B (zh) 一种延迟释放的药物组合物
HK1034032B (en) Controlled release peroral compositions of levosimendan
IE970563A1 (en) A composition
CN101244052A (zh) 一种含有降血脂成分的口服固体制剂

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20110423